Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung

View original at globenewswire.com
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung BioNTech treibt Onkologiestrategie mit dem Fokus auf zwei tumorübergreifende (Pan-Tumor)-Programme sowie Kombinationsansätze weiter voran, um das gesamte Spektrum von Krebserkrankungen vom frühen bis zum späten S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trastuzumab Pamirtecan BLA filing planned for 2026 pending FDA feedback

    80% confidence

  • BNT111 demonstrated deep durable antitumor responses with statistically significant improvement in ORR vs historical control

    80% confidence

  • 2025 revenue guidance is €2,600-2,800M

    80% confidence

  • 2025 R&D costs expected to be €2,000-2,200M, reduced from previous guidance of €2,600-2,800M

    80% confidence

  • Pumitamig showed encouraging anti-tumor activity, positive PFS trend, controlled safety profile, and low discontinuation rate in ES-SCLC Phase 2 trial

    80% confidence

  • Autogene Cevumeran showed strong durable immune responses up to 1.5 years post-treatment with broad immune response correlated with extended PFS

    80% confidence

  • BioNTech expects no positive net income for FY 2025

    80% confidence

  • 2025 CapEx expected to be €200-250M, reduced from previous guidance of €250-350M

    80% confidence

  • 2025 SG&A costs expected to be €550-650M, reduced from previous guidance of €650-750M

    80% confidence

  • ROSETTA Breast-01 Phase 3 trial for TNBC will start by end of 2025

    80% confidence

Data points we hold from this source

BioNTech SE · outstanding shares240455450 shares
BioNTech SE · r and d costs564.8 million_EUR
BioNTech SE · sg and a costs148.5 million_EUR
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung — Source | Via News | ViaNews EU